Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

Eli Lilly’s (NYSE:LLY) stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial ...

The news came as RBC Capital analyst Luca Issi initiated coverage on Argenx with an outperform rating and 850 price target, saying that doctor checks point to accelerating uptake of Vyvgart, according ...

The Trump administration’s sweeping tariffs have sent ripples through the healthcare sector in 2025. Last week, the US ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY ...